Cure8 news brief
A biosimilar to ustekinumab (Stelara) reaching more markets could increase access and lower cost for people with Crohn's disease, ulcerative colitis, and other immune-mediated conditions where ustekinumab is used.
Adult patients with Crohn's disease or ulcerative colitis (especially those on or considering ustekinumab), caregivers, and clinicians following biologic access and cost.
Biocon said it secured additional licensing to commercialize Yesintek, a proposed biosimilar to Stelara (ustekinumab), in several global markets including Australia, Brazil, China, Hong Kong, Mexico, Israel, New Zealand, Kazakhstan and South Korea.
The article notes Stelara/ustekinumab is approved for Crohn's disease, ulcerative colitis, psoriasis, and psoriatic arthritis and positions the biosimilar as a potentially more affordable option for patients in these markets. This is a business/market report about licensing and market entry, not a clinical study or regulatory approval announcement.
Patients currently taking ustekinumab or considering it should not change treatment based on this article; availability and local regulatory approvals and pricing decisions will determine when and how a biosimilar becomes an option. For clinical questions about switching to a biosimilar, discuss with your gastroenterologist or care team.
The article is sourced from a financial/news wire item republished on TradingView and focuses on market access and company stock reaction rather than clinical data.
This report describes a licensing/commercialization agreement and market entry plans; it does not report new clinical trial results or regulatory approvals in each listed market. Local regulatory status and timing, pricing, and substitution policies will determine patient impact.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Cure8 could only read part of this source from money.rediff.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Ulcerative colitis, and Ustekinumab.
An FDA interchangeability approval for a biosimilar to ustekinumab could make a lower-cost alternative more available for people with Crohn’s disease or ulcerative colitis who use Stelara. It’s primarily a regulatory and...
This approval adds an FDA-cleared IL-23 biologic (Tremfya) as a treatment option for adults with moderately to severely active Crohn’s disease, which may affect treatment choices. It also comes as multiple biosimilars to...
